Science Corporation Pioneers Commercial brain-Computer Interface Solutions
in the rapidly evolving landscape of artificial intelligence, Max Hodak, co-founder and former president of Neuralink, is leading Science Corporation toward groundbreaking advancements in brain-computer interface (BCI) technology. The company recently closed a $230 million Series C funding round, boosting its valuation to nearly $1.5 billion.
Innovative Vision Recovery with the PRIMA Implant
A centerpiece of Science Corporation’s innovation is PRIMA, an ultra-small implant roughly the size of a sesame seed designed for placement within the eye. When paired with smart glasses equipped with cameras, PRIMA aims to restore functional vision for patients suffering from advanced macular degeneration.
This technology was acquired from French firm Pixium Vision in 2024 and has as been enhanced by Science Corporation. Clinical trials involving 47 participants across Europe and North America demonstrated that 80% experienced meaningful improvements in visual acuity-enabling them to read letters, numbers, and words fluently-a breakthrough achievement for individuals who were previously blind.
“This represents the first conclusive evidence that blind patients can regain fluent reading capabilities,” Hodak remarked during a recent discussion.
navigating Regulatory Milestones Toward Market Entry
The company has submitted its submission for CE marking within the European Union and expects approval by mid-2026. This milestone would make Science Corporation one of the first BCI companies worldwide to commercialize such a device. Germany is anticipated as their initial launch market due to its efficient regulatory pathways for innovative medical technologies.
Meanwhile, ongoing dialogues with U.S. regulatory bodies continue without definitive timelines yet established.
Expanding Clinical Trials: Targeting Additional Retinal Diseases
Science Corporation is extending PRIMA’s clinical research scope by including patients diagnosed with Stargardt disease and retinitis pigmentosa-both inherited retinal conditions causing severe vision loss among younger populations globally.
Fueling Innovation Beyond Visual Restoration
The recent influx of capital will accelerate commercialization efforts while also supporting ambitious projects within Science Corporation’s research pipeline:
- Biohybrid Neural Interfaces: Crafting devices that incorporate lab-grown neurons derived from stem cells onto microstructured “waffle-like” platforms designed to biologically integrate with cortical brain circuits.
- Organ Preservation Systems: Developing compact perfusion technologies capable of sustaining organ viability during transport on commercial flights or even at home-potentially transforming organ transplantation logistics beyond traditional intensive care settings.
Diverse Investment Partners Propel Growth Trajectory
This latest funding round attracted both new investors and returning backers such as Lightspeed Venture Partners, Khosla Ventures, Y Combinator, quiet Capital alongside IQT-a nonprofit investment group focused on government-relevant technologies utilized by agencies like FBI or CIA.
Total capital raised now approaches $490 million enabling an expanding workforce currently numbering approximately 150 employees dedicated across multiple cutting-edge neuroscience and biomedical engineering initiatives worldwide.
